Cosmetics regulation: the dossier, the safety assessor and the accountable person

Somebody in the market carries the product

Most systems name a person or company established in the territory who answers for the product: they hold the file, they deal with the authority, they are contactable from the label. For an exporter that means appointing someone locally or working through an importer or distributor willing to take the role, which is a commercial negotiation as much as a regulatory step. The arrangement deserves care, because the party holding that position controls your route to that market and can be difficult to replace mid-listing without repeating administrative steps. Agree in the contract what becomes of the registration if you change partner.

The file is only as strong as the safety assessment inside it

The dossier typically pulls together formulation, specifications, manufacturing method, stability and preservative efficacy data, packaging compatibility, exposure assumptions and an assessment by someone qualified to make it. Assessors need real data about ingredients and about how the product will be used, and the common failure is a file assembled from supplier marketing sheets rather than from specifications and toxicological information. Where a contract manufacturer holds the technical detail, agree in advance what the brand owner is entitled to receive, since a file you cannot access is a file you cannot produce.

Ingredient restrictions move under your feet

Lists of prohibited and restricted substances, permitted preservatives, colourants and filters are revised as scientific opinions are issued, and a formulation compliant when launched can drift out of line. Manufacturers with long catalogues need a way to be told when a substance they use changes status and a route to reformulate, re-test stability and update artwork. This is one of the few compliance activities with a genuine recurring workload, and it is usually underestimated by brands whose formulations were developed by a supplier they no longer work with. A register mapping substances to finished products turns each new scientific opinion into a short query.

Claims are evidence, not copywriting

Statements about performance, skin benefits, natural or free-from positioning and comparative claims are examined by regulators and by competitors, and the evidence expected varies with how strong the claim is. Consumer testing, instrumental measurement and ingredient literature each support different assertions. Free-from claims attract particular scrutiny where they imply a competitor's ingredient is unsafe. The practical control is a rule that no claim reaches artwork without a documented substantiation reference, because the marketing calendar will otherwise outrun the evidence every time. Retailers increasingly ask to see the substantiation before listing, which brings the deadline forward into development.

Notification, inspection and reading the rules for each market

Many systems require a product to be notified into a central register before sale, and some also require reporting of undesirable effects. Enforcement typically falls to national market surveillance or health authorities, with the federal food and drug regulator holding the position in the United States and the European framework administered through national bodies. This overview describes structure, not obligation, and no page can tell you whether a formulation or claim is acceptable; that belongs to the authority for the market and to a regulatory specialist working from your actual formulation.

Frequently asked questions

Our contract manufacturer developed the formula. Who holds the product file?

Commercially it varies, and that is the problem: a manufacturer protecting its formulation may be unwilling to hand over full composition, while the party accountable in the market needs enough to answer an authority. Common solutions include the manufacturer holding confidential elements while providing everything else, or lodging detail with an agreed third party. Settle it in the supply agreement before launch, along with what happens to the file if the relationship ends.

Does a product sold in one region need reformulating for another?

Frequently yes, because permitted substances, concentration limits, preservative choices, colourants and labelling conventions differ, and a product acceptable in one market may need substitution elsewhere. That has knock-on effects on stability testing, artwork and stock keeping. Brands entering several markets usually decide early whether to run one global formulation constrained by the strictest applicable rules or separate variants, and each choice carries a different cost profile.

What triggers a review of an existing product's compliance?

A change to any ingredient's regulatory status, a supplier substitution or specification change, a new claim, a packaging change that could affect compatibility, a reported adverse effect, and entry into a new market. Beyond those, a periodic review of the catalogue catches slow drift, particularly for legacy lines whose files were built years ago. Keeping a register of which substances appear in which products makes each review a query rather than an investigation.